Chronic myeloid leukemia and HIV-infection by Schlaberg, Robert et al.
This article was downloaded by:[Columbia University HHMI]
On: 28 June 2008
Access Details: [subscription number 794096172]
Publisher: Informa Healthcare
Informa Ltd Registered in England and Wales Registered Number: 1072954
Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK
Leukemia and Lymphoma
Publication details, including instructions for authors and subscription information:
http://www.informaworld.com/smpp/title~content=t713643806
Chronic myeloid leukemia and HIV-infection
Robert Schlaberg a; Julie G. Fisher b; Michael J. Flamm b; Vundavalli V. Murty a;
Govind Bhagat a; Bachir Alobeid a
a Departments of Pathology,
b Medicine, Columbia University Medical Center, New York, NY, US
First Published: June 2008
To cite this Article: Schlaberg, Robert, Fisher, Julie G., Flamm, Michael J., Murty,
Vundavalli V., Bhagat, Govind and Alobeid, Bachir (2008) 'Chronic myeloid
leukemia and HIV-infection', Leukemia and Lymphoma, 49:6, 1155 — 1160
To link to this article: DOI: 10.1080/10428190802074601
URL: http://dx.doi.org/10.1080/10428190802074601
PLEASE SCROLL DOWN FOR ARTICLE
Full terms and conditions of use: http://www.informaworld.com/terms-and-conditions-of-access.pdf
This article maybe used for research, teaching and private study purposes. Any substantial or systematic reproduction,
re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly
forbidden.
The publisher does not give any warranty express or implied or make any representation that the contents will be
complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be
independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings,
demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or




































Chronic myeloid leukemia and HIV-infection
ROBERT SCHLABERG1, JULIE G. FISHER2, MICHAEL J. FLAMM2,
VUNDAVALLI V. MURTY1, GOVIND BHAGAT1, & BACHIR ALOBEID1
Departments of Pathology1 and Medicine2, Columbia University Medical Center, New York, NY, US
(Received 1 February 2008; revised and accepted 23 March 2008)
Abstract
The incidence of non-HIV-associated hematologic malignancies, including chronic myeloproliferative disorders, is
increasing in HIV-infected (HIVþ) patients. This is thought to be due to prolonged survival in the era of highly active
antiretroviral therapy (HAART). Previously, only six cases of chronic myeloid leukemia (CML) have been described in
HIVþ individuals and limited information is available regarding the management of patients with concurrent CML and HIV-
infection. We report three cases of CML in HIVþ patients who were treated with imatinib and HAART. Treatment was
generally well tolerated, and cytogenetic response (complete in two patients) was achieved with follow-up ranging from 3 to
69 months. HIV viral load remained undetectable and CD4 cell counts were stable in all three patients. Concurrent
treatment with imatinib and HAART can result in appropriate control of CML and HIV-infection as well as long-term
survival.
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Introduction
Human immunodeficiency virus-infected (HIVþ)
individuals are at high risk for developing neoplasms.
Malignancies are responsible for 25–30% of all
deaths in patients treated with highly active anti-
retroviral therapy (HAART) [1,2], as compared with
only 10% in the pre-HAART era [3,4]. The
increased malignancy-related mortality is most likely
a result of decreasing opportunistic infections,
prolonged survival and development of age-related
neoplasms [2,5–7].
Hodgkin lymphoma and multiple myeloma are the
most frequently reported non-AIDS-defining hema-
tologic malignancies in HIV-infected individuals [2].
Sporadic cases of chronic myeloproliferative disor-
ders (CMPD), such as polycythemia vera, hypereo-
sinophilic syndrome and mast cell disorders have also
been reported [8–16]. To this date, six cases of
chronic myeloid leukemia (CML) have been de-
scribed in HIVþ individuals, only two of which were
treated with current regimens [17]. One patient was
concurrently treated with imatinib and HAART, and
the other patient received an allogeneic bone marrow
transplant in combination with HAART. Experience
regarding the treatment of CML in HIVþ individuals
is limited and several considerations warrant special
attention: both conditions as well as their respective
therapies may cause bone marrow failure and
pharmacological interactions between HAART and
imatinib may require adjustment of therapy.
We report on three HIVþ patients diagnosed with
CML in our institution. All three patients were
successfully treated with HAART and imatinib and
have sustained cytogenetic remission (complete in
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core biopsies, Giemsa-stained, air-dried bone mar-
row aspirate smears and Wright-stained, air-dried
peripheral blood smears were reviewed.
Immunohistochemistry
Immunohistochemical staining was performed on
paraffin-embedded tissue sections with primary
antibodies directed against CD34, CD117, MPO,
Glycophorin A and CD61 using standard methods.
Flow cytometry
Three or four-colour flow cytometric analysis
(FACScan; Becton Dickinson, San Diego, CA) was
performed on peripheral blood and bone marrow
aspirate samples using standard procedures and data
were analysed using the Cell Quest software (Becton
Dickinson). Lymphoid (T-, B-, NK-cell) and mye-
loid/monocytic lineage specific/associated antigens
were analysed using a comprehensive panel of
monoclonal antibodies.
Cytogenetics
Giemsa banded karyotype analysis was performed on
metaphase preparations from overnight cell cultures
without mitogen stimulation using standard meth-
ods. Karyotypes were described according to ISCN
2005 [18]. Fluorescence in situ hybridisation (FISH)
analysis was performed on standard chromosome
preparations using BCR/ABL Dual Color, Dual
Fusion Translocation Probe (Abbott Molecular,
Des Plaines, IL) and standard protocols. Quantita-
tive FISH analyses and follow-up examinations were
performed on 500 interphase nuclei.
Patient 1
A 62-year-old Caucasian male with a 16-year history
of HIV-infection, recurrent thrush and abdominal
DLBCL was incidentally found to have leukocytosis
(44,700/mL, reference range: 3500–9100) and mild
macrocytic/hypochromic anemia (Hb 12.6 g/dL,
reference range: 13.3–16.2; MCV 101.8 fl, reference
range: 79.0–93.3; MCHC 31.4 g/dL, reference
range: 32.3–35.9). The patient had received
HAART for the past 3 years (most recently
nevirapine, abacavir/lamivudine/zidovudine) and
had achieved complete virological (550 copies/
mL) and immunologic (CD4 cell count 488/mL,
reference range: 393–1489) response. His past
medical history was significant for DLBCL diag-
nosed 22-months prior. Treatment with 6 cycles of
R-CHOP had been completed over the ensuing 14
months.
At presentation, a differential count showed 57%
neutrophils, 6% basophils, 1% metamyelocytes, 2%
myelocytes, 5% atypical lymphocytes and 0.5%
nucleated RBC. Serum chemistry evaluation was
significant only for a mildly increased creatinine of
1.9 mg/dL (reference range: 0.6–1.2).
Bone marrow examination showed hypercellularity
(495%) due to marked myeloid and megakaryocytic
hyperplasia, without increase in blasts. Karyotypic
analysis revealed a t(9;22)(q34;q11.2) translocation
in 20 out of 20 metaphases (Figure 1). FISH analysis
using BCR/ABL dual fusion probes showed a nuclear
fusion signal in 93.3% of interphase nuclei (Figure 1).
The diagnosis of chronic phase CML was estab-
lished, the prognostic Sokal index was 1.08
(intermediate-risk), and the Hasford score was
1211.9 (intermediate-risk). Treatment with 600 mg
imatinib daily was initiated, which the patient
tolerated without any side effects or complications.
Hematologic remission with persistent mild throm-
bocytopenia (1156109/L) was achieved within 6
weeks of diagnosis. Cytogenetic follow-up, 3 months
after initial diagnosis, revealed a minor cytogenetic
response (74% Phþ cells in peripheral blood). A
CBC at this time demonstrated hematologic remis-
sion with a WBC of 46109/L, Hb of 11.4 g/dL and
platelet count of 1296109/L.
No further cytogenetic follow-up was available.
Mean WBC, Hb and platelet counts during 19
months of follow-up were 4.76109/L, 13.3 g/dL and
1426109/L, respectively. The patient’s viral load
remained undetectable (550 copies/mL), and the
most recent CD4 cell count was 488 cells/mL.
Patient 2
A 57-year-old African American male with a 17-year
history of HIV-infection previously complicated by
oral thrush and Pneumocystis carinii (jiroveci) pneu-
monia presented with vomiting, diarrhea and 7.5 kg
weight loss over 3 months. The patient had received
HAART for the past 3 years (lopinavir/ritonavir,
abacavir/lamivudine/zidovudine), which resulted in
complete virological (550 copies/mL) and immuno-
logic (CD4 count of 508/mL) response. He had been
diagnosed with squamous cell carcinoma of the
larynx 5 years prior (treated with total laryngectomy
and radiation therapy), chronic hepatitis C virus
infection 6 years prior, coronary artery disease,
diabetes mellitus and hypertension.
At presentation, he had mild hepatomegaly
and leukocytosis (48,000/mL) with 40% neutrophils,
8% basophils, 5% metamyelocytes, 13% myelocytes,
5% promyelocytes, 9% myeloblasts and 5%
nucleated RBC, macrocytic normochromic anemia
(Hb 9.4 g/dL, MCV 108.6 fl, MCHC 32.5 g/dL),



































and mild thrombocytopenia (1196109/L). Serum
chemistry evaluation was significant for a lactate
dehydrogenase (LDH) level of 1998 U/L (reference
range 115–221 U/L) and mildly increased aspartate
amino transferase (AST, 56 U/L, reference range 12–
38 U/L).
Bone marrow examination showed hypercellularity
(close to 100%) with marked myeloid hyperplasia,
10% myeloblasts and 8% basophils. Karyotypic
analysis revealed a t(9;22)(q34;q11.2) translocation
in 20 out of 20 metaphases analysed and FISH
identified a BCR/ABL fusion signal in 91% of
interphase nuclei (Figure 1). The diagnosis of
CML was made, the prognostic Sokal index was
1.36 (high-risk), and the Hasford score was 2380.7
(high-risk). Treatment with imatinib (400 mg/day)
Figure 1. Microscopic and cytogenetic findings of cases 1 through 3 (case 1: panels A and D; case 2: panels B and E; case 3: panels C and F).
Marked hypercellularity and florid myeloid hyperplasia are evident in panels A, B and C. Small and hypolobated megakaryocytes,
characteristic of CML, are shown in insets A and C. A significant leftshift of myeloid maturation with increased immature myeloid precursors
is evident in panel and inset B. H&E stains, 2006magnification (insets 4006). Partial Giemsa-banded karyotype (insets D–F) and FISH
analysis using bcr/abl dual fusion probe of CML cases (panels D–F). Arrows indicate fusion signals resulting from t(9;22). Case 3 (panel and
inset F) is a variant translocation t(9;22)(q22;q11.2) resulting in deletion on derivative 9 chromosome and 1 fused, 1 red, 2 green signal
pattern compared to the usual 2 fused, 1 green, 1 red pattern in other cases.



































was initiated and complete hematologic remission
was achieved within 2 weeks.
The patient was started on erythropoietin treat-
ment (40,000 U/week) 2 weeks after initiation of
imatinib (Hb 8.4 g/dL) and was admitted 6 weeks
later with persistent anemia (Hb 4.9 g/dL, reticulo-
cyte count 0.1%). A bone marrow biopsy showed
100% cellularity with myeloid hyperplasia and
markedly decreased erythroid progenitors. The
erythropoietin dose was increased to 80,000 U/
week and imatinib was paused for 3 weeks. However,
anemia persisted and 2 weeks after re-starting
imatinib (300 mg/day) the HAART regimen was
modified replacing abacavir/lamivudine/zidovudine
with emtricitabine/tenofovir (to eliminate abacavir)
and lopinavir/ritonavir with efavirenz (to eliminate
ritonavir). In addition, imatinib was paused for 4
weeks and erythropoietin was discontinued. After
these modifications, anemia gradually resolved over
the ensuing 4 months. No follow-up bone marrow
biopsy was performed.
FISH analysis of peripheral blood showed persis-
tence of CML 7 months after diagnosis (fusion signal
in 43.8% of cells), and complete cytogenetic remis-
sion was attained 13 months after diagnosis. Mean
WBC, platelet count and Hb during 20 months of
follow-up were 3.66109/L, 1316109/L and 13.3
g/dL, respectively. Viral load remained undetectable
(550 copies/mL) and the most recent absolute CD4
cell count was 382 cells/mL.
Patient 3
A 61-year-old Hispanic male with an 11-year history
of HIV-infection presented with hepatomegaly,
thrombocytosis, anemia and a normal WBC. The
patient had been receiving HAART for more than 10
years (most recently: nevirapine, abacavir, lamivu-
dine) resulting in sustained virologic (550 copies/
mL) and immunologic (CD4 count 523/mL) re-
sponse. His past medical history was significant for
chronic renal insufficiency, coronary artery disease,
hypertension, hypercholesterolemia and an adrenal
tumor of unclear type that had been resected at an
outside hospital 20 years prior.
A CBC revealed thrombocythemia (410006109/
L), macrocytic anemia (Hb 9.7 g/dL, MCV 128.5 fl,
MCHC 33.1 g/dL), a normal WBC (8600/mL) and a
differential count of 43% neutrophils, 3% basophils,
3% metamyelocytes, 5% atypical lymphocytes and 1%
nucleated red blood cells. Serum chemistry evaluation
was significant for hyperkalemia (5.8 mM/L, reference
range 3.6–5.0), and elevated creatinine 1.8 mg/dL.
Bone marrow examination showed hypercellularity
(90%) with myeloid and megakaryocytic hyperplasia
and 9% myeloblasts. Karyotypic analysis demon-
strated a variant t(9;22)(q22;q11.2) translocation in
20 of 20 metaphases and FISH revealed BCR/ABL
fusion genes in 83% of cells (Figure 1). The patient’s
prognostic Sokal index was 1.57 (high-risk) and the
Hasford score was 1440.3 (intermediate-risk).
Imatinib treatment (400 mg/day) resulted in a
partial hematologic remission with mean platelet
count of 6076109/L, WBC of 2000/mL and Hb of
7.9 g/dL over the ensuing 4 months. He developed
persistent anemia (nadir 6.9 g/dL), which required
erythropoietin treatment, red blood cell transfusion
and discontinuation of imatinib therapy. One month
later, after improvement of the patient’s anemia (Hb
11.5 g/dL), imatinib was reinstituted at a dose of
200 mg and gradually increased to 400 mg over 16
months. Erythropoietin treatment was discontinued
and the patient maintained a mean Hb of 12.8 g/dL,
mean WBC of 4400/mL and mean platelet count of
1596109/L during the ensuing follow-up. Complete
cytogenetic response was demonstrated by periph-
eral blood FISH analysis 17 months after diagnosis
and maintained during the entire follow-up
period. HIV viral load remained undetectable
(550 copies/mL) and the most recent CD4 cell
count was 440/mL.
Discussion
With long-term survival of HIVþ patients in the era
of HAART, non-HIV-associated hematologic malig-
nancies are being encountered more frequently [8–
16]. Six HIVþ patients with CML have previously
been reported [17]. We describe three additional
cases of HIVþ individuals who were diagnosed with
CML at our institution between 2000 and 2006
(Table I). All three patients were males, received
HAART at the time of diagnosis, and were older
(mean: 60 years, range: 57–62 years) than previously
reported patients (mean: 33 years, range: 9–48
years). Imatinib has recently been recommended by
an international expert panel as first line treatment
for early chronic phase Phþ CML and for patients
who are not eligible for allogeneic hematopoietic cell
transplantation [19]. However, scant information
exists on treatment response to imatinib in HIVþ
individuals.
All three patients in our series responded well to
concurrent HAART and imatinib therapy. Cytoge-
netic response was achieved in all patients (complete
in two). Long-term cytogenetic follow-up was avail-
able in two patients, both of whom maintained
complete response over a period of 20–69 months.
Patient 1 was not available for cytogenetic follow-up
after having achieved a minor cytogenetic response
at 3 months. All three patients maintained
stable hemoglobin, leukocyte and platelet counts.



































Molecular response was not routinely monitored.
Furthermore, the patients’ HIV-infection remained
well controlled since initiation of imatinib treatment.
All three patients have sustained stable CD4 cell
counts and suppression of viral replication.
Concurrent treatment for HIV-infection and CML
was generally well tolerated. The course of two
patients was initially complicated by anemia necessi-
tating erythropoietin therapy and brief interruption of
imatinib treatment. Imatinib is mainly metabolised
by the cytochrome P450 (CYP) 3A4 isoenzyme and
concurrent administration of numerous antiretroviral
and antimicrobial drugs that inhibit CYP3A4 may
lead to drug–drug interactions [20–22]. In the future,
quantification of imatinib plasma concentrations by
high-performance liquid chromatography or mass
spectrometry might prove useful when suspecting
toxicity or observing inadequate treatment response
[23–25].
Bone marrow abnormalities are routinely ob-
served in HIVþ individuals (dyspoiesis, denuded
megakaryocyte nuclei) and lifetime exposure to
AZT has been shown to result in myelodysplasia in
an animal model [18,26]. However, there is no
data indicating that HIV-infection or chronic
antiretroviral therapy may increase the risk of
myelodysplastic or myeloproliferative disorders in
humans and the occurrence of CML in HIVþ
patients is most likely coincidental.
Over the past decade, great progress has been
made in the treatment of both CML and HIV. With
current regimens, both conditions can be controlled
through chronic therapy. It is encouraging for a
growing number of affected patients that concurrent
treatment of both CML and HIV is safe, effective,
and can result in long-term survival.
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